Table 1. General characteristics of the study population.
| Parameters | Arbekacin (n = 20) |
Vancomycin (n = 36) |
P value* |
|---|---|---|---|
| Age (range), yr | 59 (36-76) | 53 (24-73) | 0.082 |
| Sex | 0.809 | ||
| Male | 9 (45) | 15 (41.7) | |
| Female | 11 (55) | 21 (58.3) | |
| Clinical status | 0.686 | ||
| CSOM without cholesteatoma | 14 (70.0) | 27 (75.0) | |
| CSOM with cholesteatoma | 6 (30.0) | 9 (25.0) | |
| Underlying disease | 0.026 | ||
| No | 6 (30.0) | 22 (61.1) | |
| Yes | 14 (70.0) | 14 (38.9) | |
| CVD | 12 (60.0) | 7 (19.4) | |
| Diabetes mellitus | 4 (20.0) | 5 (13.9) | |
| Cancer | 2 (10.0) | 1 ( 2.8) | |
| Pulmonary disorders | 1 ( 5.0) | 1 ( 2.8) | |
| Hypothyroidism | 1 ( 5.0) | 1 ( 2.8) | |
| Others† | 1 ( 5.0) | 5 (13.9) | |
| Previous antibiotics | 0.357 | ||
| No | 1 (5.0) | - | |
| Yes | 19 (95.0) | 36 (100) | |
| Aminoglycosides | 14 (70.0) | 28 (77.8) | |
| Quinolones | 12 (60.0) | 3 (8.3) | |
| Cephalosporins | 9 (45.0) | 33 (91.7) | |
| Penicillins | 3 (15.0) | 2 (5.6) | |
| Concomitant antibiotics | 0.209 | ||
| No | 16 (80.0) | 23 (63.9) | |
| Yes | 4 (20.0) | 13 (36.1)‡ | |
| Cephalosporins | 4 (20.0) | 7 (5.6) | |
| Quinolones | 0 (0.0) | 4 (8.3) | |
| Others | 0 (0.0) | 4 (8.3) | |
| Medication duration (range) days | 0.324 | ||
| Systemic therapy | 9 (4-42) | 10 (4-27) | |
| The success rate of tympanic membrane | 100% (17/17)§ | 75% (27/30)∥ | 0.292 |
| Polymicrobial infection | 0.691 | ||
| No | 17 (85.0) | 32 (88.9) | |
| Yes | 3 (15.0) | 4 (11.1) | |
| P. aeruginosa | 2 (10.0) | 4 (11.1) | |
| K. pneumoniae | 1 ( 5.0) | 0 (0.0) |
Data are presented as either the median (range) or number (proportion). CVD, Cardiovascular disease; CSOM, chronic suppurative otitis media. *Analyzed by the Mann-Whitney U test, chi-square test or Fisher's exact test; †Osteoporosis (1), mental retardation (1), hepatitis (2), BPH (1), and hemiparesis (1); ‡Two patients were treated by two concomitant antibiotics (aminoglycoside and cephalosporin); §3 Missing; ∥6 Missing.